Showing 1,821 - 1,840 results of 119,177 for search '(( a mean decrease ) OR ( 5 ((((point decrease) OR (fold decrease))) OR (a decrease)) ))', query time: 1.74s Refine Results
  1. 1821
  2. 1822
  3. 1823
  4. 1824
  5. 1825
  6. 1826
  7. 1827
  8. 1828

    List of selected metabolites that associate with diabetes at q-values <0.05 using log-scaled metabolite concentrations and assuming a linear model; %change is the increase or decrease of the mean in the diabetes group with respect to the control group; eta<sup>2</sup> is the proportion of the total variance that can be explained by the factor “diabetes” in the linear model; N is the number of valid data points that entered the analysis; the platform on which the corresponding metabolite was measured is indicated by the first letter of the provider: B = Biocrates, C = Chenomx, M = Metabolon. by Karsten Suhre (67967)

    Published 2010
    “…<p>List of selected metabolites that associate with diabetes at q-values <0.05 using log-scaled metabolite concentrations and assuming a linear model; %change is the increase or decrease of the mean in the diabetes group with respect to the control group; eta<sup>2</sup> is the proportion of the total variance that can be explained by the factor “diabetes” in the linear model; N is the number of valid data points that entered the analysis; the platform on which the corresponding metabolite was measured is indicated by the first letter of the provider: B = Biocrates, C = Chenomx, M = Metabolon.…”
  9. 1829
  10. 1830
  11. 1831
  12. 1832
  13. 1833
  14. 1834

    VRK1 overexpression is seen in human breast cancer and is associated with decreased relapse-free survival. by Aye M. Mon (5714912)

    Published 2018
    “…Data for cancer subtypes are shown in boxes numbered 1–11: 1: benign breast neoplasm (rank 6459, 1.4 fold-change, NS), 2: breast carcinoma (rank 833, 1.5 fold-change, p = 3.83x10<sup>-5</sup>), 3: breast phyllodes tumor (rank 512, 1.2 fold-change, p = 0.002), 4: ductal breast carcinoma in situ (rank 1969, 1.5 fold-change, p = 0.002), 5: invasive breast carcinoma (rank 1060, 1.6 fold-change, p = 1.28x10<sup>-5</sup>), 6: invasive ductal and invasive lobular breast carcinoma (rank 941, 1.5 fold-change, p = 6.76x10<sup>-22</sup>), 7: invasive ductal breast carcinoma (rank 613, 1.5-fold change, p = 2.71x10<sup>-71</sup>), 8: invasive lobular breast carcinoma (rank 947, 1.3 fold-change, p = 3.64x10<sup>-28</sup>), 9: medullary breast carcinoma (rank 400, 1.8 fold-change, p = 3.25x10<sup>-12</sup>), 10: mucinous breast carcinoma (rank 1932, 1.4 fold-change, p = 7.41x10<sup>-10</sup>) and 11: tubular breast carcinoma (rank 1253, 1.4 fold-change, p = 1.24x10<sup>-17</sup>). …”
  15. 1835
  16. 1836

    Hsp72 overexpression decreases total NF-κB-p65 in resting cells and reduces steady state IκBα protein levels. by Patrick W. Sheppard (586664)

    Published 2014
    “…Gray data points are rescaled from <a href="http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1003471#pcbi-1003471-g001" target="_blank">Fig. 1B</a>. …”
  17. 1837
  18. 1838

    Pan-JAK inhibitor P6 decreased ISG expression and increased susceptibility of BEAS-2B cells to H1N1 influenza virus infection. by Lai-Giea Seng (644370)

    Published 2014
    “…BEAS-2B cells were pre-treated with P6 at a final concentration of 2.5 or 5 µM for 24 h and infected with H1N1 influenza virus at 1.0 MOI (based on MDCK cells). …”
  19. 1839

    Possible Points of Canonical Wnt Inhibition. by Laura Corbett (826084)

    Published 2015
    “…<p>This study has highlighted six possible points of canonical Wnt inhibition occurring in HSCs. (1) Predominantly non-canonical ligand expression. …”
  20. 1840